Processa Pharmaceuticals, INC

Processa Pharmaceuticals has acquired Vidya Therapeutics and secured approximately $200 million in a private placement to advance Vidya's lead asset, VT-7208, through key clinical milestones.

Dr. Sian Bigora, Chief Development and Regulatory Officer, will transition to a part-time role effective May 1, 2026.

Processa Pharmaceuticals, Inc. announced it has regained compliance with NASDAQ's minimum bid price requirement, closing the matter.

Processa Pharmaceuticals, Inc. has filed a Certificate of Amendment to effect a 1-for-25 reverse stock split of its common stock, effective December 16, 2025.

Processa Pharmaceuticals shareholders approved increasing authorized common stock, a reverse stock split, and an expanded incentive plan.

Processa Pharmaceuticals shareholders approved proposals to increase authorized shares, effect a reverse stock split, and expand its incentive plan.

Processa Pharmaceuticals reported increased net losses in Q3 2025, continued reliance on capital raises, and is pursuing a new cryptocurrency treasury strategy while advancing its oncology pipeline.

Processa Pharmaceuticals, Inc. reported an increased net loss for Q2 2025 but significantly strengthened its cash position through recent public offerings, extending its capital runway into Q1 2026 while facing ongoing going concern doubts and Nasdaq listing challenges.

Processa Pharmaceuticals' Q1 2025 results show a net loss of $2.83 million, with ongoing progress in clinical trials for NGC-Cap and a recent public offering providing $4.4 million in net proceeds.

Processa Pharmaceuticals reported a net loss of $3.38 million for the third quarter of 2024 and initiated a Phase 2 trial for its lead drug candidate, NGC-Cap.

Processa Pharmaceuticals reported a net loss of $3.01 million for the second quarter of 2024, while progressing its oncology drug pipeline, including initiating a Phase 2 trial for NGC-Cap.

Processa Pharmaceuticals reported a net loss of $2.7 million for the first quarter of 2024, while making progress on its NGC-Cap program and securing funding for future trials.

Processa Pharmaceuticals files an amendment to its 2025 Annual Report to provide required disclosures regarding executive compensation, governance, and director information.

Processa Pharmaceuticals, a clinical-stage biopharmaceutical company, details its 2024 financial results and strategic focus on developing Next Generation Cancer (NGC) therapies with improved safety and efficacy profiles.

Processa Pharmaceuticals' 10-K filing highlights a strategic shift towards Next Generation Chemotherapy (NGC) oncology drugs, while reporting a net loss of $11.1 million for 2023.

Sheila Gujrathi, a Director of Processa Pharmaceuticals, Inc., reported multiple transactions in common stock on July 28, 2026.

Justin W Yorke, a Director of Processa Pharmaceuticals, Inc., received 33,500 shares of common stock on July 26, 2026.

Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals, Inc., received 11,883 shares of common stock on July 26, 2026.

Geraldine Pannu, a Director of Processa Pharmaceuticals, Inc., received 33,500 shares of common stock on July 26, 2026.

George K Ng, Chief Executive Officer and a Director of Processa Pharmaceuticals, Inc., received 9,384 shares of common stock on July 26, 2026.

James R Neal, a Director of Processa Pharmaceuticals, Inc., received 62,221 shares of common stock on July 26, 2026.

Processa Pharmaceuticals, Inc. announced a change in the physical location for its upcoming 2025 Special Meeting of Stockholders.

Processa Pharmaceuticals, Inc. calls a Special Meeting to vote on increasing authorized shares, a reverse stock split, and expanding its incentive plan.

Processa Pharmaceuticals announces its 2025 Annual Meeting of Stockholders to be held on June 30, 2025, to vote on director elections, warrant share issuance, auditor ratification, and executive compensation.

Processa Pharmaceuticals has filed a definitive proxy statement with the SEC.

Processa Pharmaceuticals provides a supplement to its definitive proxy statement, detailing the relationship between executive compensation and company performance metrics like total shareholder return and net income.

Processa Pharmaceuticals has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Processa Pharmaceuticals, a clinical-stage biopharmaceutical company, is conducting a public offering of common stock and warrants to raise up to $7.0 million, aiming to fund its Phase 2 clinical trial for NGC-Cap and address its significant accumulated deficit and going concern issues.

Processa Pharmaceuticals is seeking to raise capital through a public offering of common stock, pre-funded warrants, and common stock purchase warrants.

Processa Pharmaceuticals has filed an amendment to its registration statement for a public offering of up to 9,400,705 shares of common stock, pre-funded warrants, and common warrants.

Processa Pharmaceuticals is launching a public offering of common stock and pre-funded warrants to raise capital for its NGC-Cap Phase 2 clinical trial and general corporate purposes.

Processa Pharmaceuticals is launching a public offering to raise capital for a Phase 2 clinical trial of its NGC-Cap drug and for general corporate purposes.

The Chiliz Group Ltd. has increased its beneficial ownership in Processa Pharmaceuticals, Inc. to 13.0% through a recent share purchase.

Chiliz Group Ltd. has acquired a 10.9% stake in Processa Pharmaceuticals, Inc. for approximately $1.24 million, citing a strategic investment in biotech-fintech convergence.

HX Entertainment Ltd., controlled by blockchain entrepreneur Alexandre Dreyfus, has acquired a 10.9% stake in Processa Pharmaceuticals, Inc. for investment purposes, aligning with Processa's exploration of cryptocurrency treasury strategies.

CVI Investments, Inc. and Heights Capital Management, Inc. report a combined 7.0% beneficial ownership of Processa Pharmaceuticals, Inc. common stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported beneficial ownership of 8.1% of Processa Pharmaceuticals, Inc. common stock.

CVI Investments and Heights Capital Management report a 9.0% beneficial ownership stake in Processa Pharmaceuticals, primarily through warrants.

Armistice Capital and Steven Boyd have reduced their beneficial ownership in Processa Pharmaceuticals, Inc. to 4.99% of common stock.

CVI Investments, managed by Heights Capital Management, has reported a 9.9% beneficial ownership stake in Processa Pharmaceuticals, Inc. through warrants.

Intracoastal Capital LLC and its principals, Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in Processa Pharmaceuticals, Inc. through a warrant.